Dan has undertaken primary due diligence responsibilities on more than a dozen of Arboretum’s new and follow-on investments including NeuMoDx, Rethink, Strata Oncology, and SI-BONE. Dan currently serves as a board director for Jumpcode Genomics, Flosonics Medical, and Akadeum Life Sciences. Previously, Dan served on the board of IntelliCyt (acquired in 2016) and was board chair of Swift Biosciences (acquired in 2021) and Dropworks (acquired in 2021). Dan was a recipient of the National Venture Capital Association’s Rising Star Award in 2020.
Prior to joining Arboretum, Dan was a Financial Analyst at Eli Lilly & Company, supporting the company’s U.S. sales and marketing operations. Dan currently serves on the Investment Advisory Board for the Michigan Biomedical Venture Fund at the University of Michigan.
Dan earned a BBA and an MBA from the Ross School of Business at the University of Michigan.